The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure. The FDA has approved Hibsago (bepirovirsen), GSK’s antisense oligonucleotide, for adults with chronic hepatitis B who are already taking…
NASHVILLE — In this Healio video, Arun B. Jesudian, MD, discusses hepatitis B developments including new therapies for highly selective patients, updated treatment guidelines and different vaccination recommendations from the ACG Annual Meeting.“The hepatitis B space is changing and, particularly,…
Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights. The US Food and Drug Administration (FDA) has approved an update to the prescribing information for risankizumab-rzaa (SKYRIZI; AbbVie), revising recommendations surrounding…
Jascayd shown to slow lung function decline in 2 Phase 3 clinical trials Written by Marisa Horak, MS | Oct. 21, 2026 Health Canada has approved Boehringer Ingelheim‘s oral therapy Jascayd (nerandomilast) as a treatment for adults with idiopathic pulmonary fibrosis (IPF) or progressive…
A five-center cohort study of 9,828 patients across the Greater Bay Area found PCSK9 inhibitor uptake surged in mainland China after 2021 reimbursement changes, while Hong Kong and Macau lagged despite similar LDL-C reductions of 38 to 56 percent wherever treatment began.
The study set out to characterize how NK cell phenotypes, receptor expression and cytokine profiles change during this combination regimen and how those changes relate to clinical outcomes. HBsAg loss remains a major challenge in chronic hepatitis B, and identifying…
ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous autoinjector for adults living with generalized myasthenia gravis (gMG) in the U.S.¹ ZILBRYSQ now offers two self-administration options for adults living with gMG who are anti-acetylcholine…
17 Dec, 2025, 08:00 CST Historical Inheritance: From Folk Remedies to a Publicly Listed Company Technological Innovation: A Key Breakthrough for the Modernization of Hakka Medicine On the raw materials side, Jiaying Pharmaceutical invested in a borneol production base to achieve direct supply…
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size. ACT Brief: Applied Clinical Trials at 2026 SCRS…
Apr 26, 2010, 09:00 ET Rimando and colleagues at other institutions have continued to study the compound. Preliminary results of a new study of its effectiveness for protecting cognitive function against age-related diseases, completed by Rimando and scientists at Case Western Reserve University,…
FDA approvals and rejections of biotech medicines - drugs, biologics, cell and gene therapies - accelerated approvals and advisory committee votes.
An article joins this feed when it matches these terms. Each one is also a search of its own.